ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Organoid models: Regulations and prospects for the development of investigational new drugs.Chinese medical journal · 2026Review
- Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer.Microsystems & nanoengineering · 2025Article
- A LRELHLNNN-Gal‑3 Modified Adipose Decellularized Scaffold To Construct Colorectal Cancer Model for Anticancer Drug Screening and Immunotherapy.ACS omega · 2025Article
- Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer.Scientific reports · 2025Article
- Precision medicine research progress based on colorectal cancer organoids.Discover oncology · 2025Review
- ECM characterization and 3D bioprinted models of NSCLC for investigating stiffness-dependent tumor behavior and drug response.Materials today. Bio · 2025Article
- From mechanisms to precision medicine: the role of organoids in studying the gut microbiota-tumor microenvironment axis.Frontiers in microbiology · 2025Review
- Advancing cancer research through organoid technology.Journal of translational medicine · 2024Review
- Review
- Article
- Distinct molecular profiles drive multifaceted characteristics of colorectal cancer metastatic seeds.The Journal of experimental medicine · 2024Article
- Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine.Molecular cancer · 2024Review
- Advances in the application of colorectal cancer organoids in precision medicine.Frontiers in oncology · 2024Review
- A PDA-Functionalized 3D Lung Scaffold Bioplatform to Construct Complicated Breast Tumor Microenvironment for Anticancer Drug Screening and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- [Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Colonic stem cells from normal tissues adjacent to tumor drive inflammation and fibrosis in colorectal cancer.Cell communication and signaling : CCS · 2023Article
- Standard: Human intestinal cancer organoids.Cell regeneration (London, England) · 2023Article
- Overview of research progress and application of experimental models of colorectal cancer.Frontiers in pharmacology · 2023Review
- The applications and techniques of organoids in head and neck cancer therapy.Frontiers in oncology · 2023Review
- Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Pre-existing drug resistance and tumorigenicity of cancer cells are highly correlated with therapeutic failure and tumor growth. However, current cancer models are limited in their application to the study of intratumor functional heterogeneity in personalized oncology. Here, an innovative two-dimensional (2D) and three-dimensional (3D) model for patient-derived cancer cells (PDCCs) and air-liquid interface (ALI) organotypic culture is established from colorectal cancer (CRC). The PDCCs recapitulate the genomic landscape of their parental tumors with high efficiency, high proliferation rate, and long-term stability, while corresponding ALI organotypic cultures retain histological architecture of their original tumors. Interestingly, both 2D and 3D models maintain the transcriptomic profile of the corresponding primary tumors and display the same trend in response to 5-Fluoruracil, regardless of their difference in gene expression profiles. Furthermore, single-cell-derived clones() are efficiently established and pre-existing drug-resistant clones and highly tumorigenic clones within individual CRC tumors are identified. It is found that tumorigenic cancer cells do not necessarily possess the stem cells characteristics in gene expression. This study provides valuable platform and resource for exploring the molecular mechanisms underlying the pre-existing drug resistance and tumorigenicity in cancer cells, as well as for developing therapeutic targets specifically for pre-existing drug-resistant or highly tumorigenic clones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.